However, conflicting studies have presented divergent views, asserting that PD-L1 expression in CTCs does not significantly affect the prognosis of lung cancer immunotherapy, and PD-L1 expression in tissues remains independent of CTCs [227, 228]. This evidence concerns the gene CD274 and lung carcinoma.